Overview

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.
Phase:
Phase 3
Details
Lead Sponsor:
Graceway Pharmaceuticals, LLC
Treatments:
Imiquimod